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Summary
Background:  The  incidence/prevalence  of  tuberculosis  (TB)  is  reported  to  be  high  in
the  Sahariya  tribe  of  North  Central  India.  The  outbreaks  of  different  drug-resistant
isolates  of  Mycobacterium  tuberculosis  emphasized  the  need  for  continuous  moni-
toring  of  resistance  to  anti-tuberculosis  drugs.  This  study  aimed  to  assess  the  proﬁle
of  multidrug  resistant  TB  among  the  Sahariya  tribe  and  their  non-tribal  neighbors
for  ﬁrst  line  drugs  through  ﬁeld-based  investigations.
Methodology:  A  total  of  274  sputum  positive  pulmonary  TB  individuals  were  enrolled
and  studied  for  their  drug  susceptibility  proﬁle  by  the  proportion  method.
Results:  A  total  of  21  cases  from  Sahariya  and  6  from  non-tribes  were  identiﬁed
with  MDR-TB.  Thus  Sahariya  tribe  showed  a  1.95-fold  increased  risk  of  developing
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Introduction
Globally,  tuberculosis  (TB),  caused  by  Mycobac-
terium tuberculosis  remains  a  major  cause  of
death. Each  year,  approximately  8.6—9.4  million
people develop  TB  (incident  cases)  and  approxi-
mately 1.5  million  deaths  occur  due  to  TB  among
HIV negative  individuals,  whereas,  0.4  million
deaths occur  from  HIV  associated  TB  throughout
the world.  In  2013,  the  approximate  proportion
of TB  cases  from  Asia  was  56%,  while,  it  was
only 29%  from  Africa.  India  is  at  the  top  among
six high  burden  countries  with  maximum  num-
ber of  incident  cases  (2.0—2.3  million)  [1]. In
Sahariya  tribe,  the  overall  prevalence  of  tuberculo-
sis is  1518/100,000  people  [2].  Multidrug  resistant
(MDR-TB)  and  extensively  drug-resistant  (XDR-TB)
tuberculosis  are  emerging  as  a  greater  threat  and
causing higher  mortality  rates.  The  MDR-TB  is
deﬁned  as  resistance  against  the  two  most  potent
anti-tuberculosis  drugs,  namely,  isoniazid  (INH)  and
rifampicin (RIF).  XDR-TB  is  attributed  to  the  clini-
cal isolate  that  is  multidrug  resistant  and  has  also
developed  resistance  to  ﬂuoroquinolones  and  to
one of  the  injectable  drugs,  such  as  amikacin,
kanamycin or  capreomycin.  Polydrug  resistance
refers to  M.  tuberculosis  isolates  that  are  resis-
tant to  more  than  one  of  the  ﬁrst  line  drugs,
other than  isoniazid  and  rifampicin.  Monodrug  resis-
tance speciﬁes  the  isolates  that  are  resistant  to
at least  one  anti-tuberculosis  drug  [3].  Detection
of drug-resistant  tuberculosis  is of  major  impor-
tance to  determine  the  ill  effects  of  these  strains
on the  health  of  affected  individuals  [4]. Several
studies have  reported  an  increase  in  the  num-
ber of  drug-resistant  TB  cases  in  India  [4—7].  In
this study,  our  aim  was  to  investigate  the  status
of multidrug  resistant  tuberculosis  in  a  primitive
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es.  Signiﬁcant  differences  were  observed  for  developing
ariya  males  and  females  when  analyzed  for  resistance
erall  drug  resistance  vs.  sensitive  isolates,  respectively.
r  MDR-TB  among  the  smokers  of  Sahariya  tribe,  whereas,
ny  signiﬁcant  association.
tibility  proﬁle  developed  in  the  present  study  indicates
osis  is  emerging  as  a  serious  public  health  concern  in
ective  control  measures  and  better  management  policies
n  of  MDR-TB  in  the  tribe.
ziz  University  for  Health  Sciences.  Published  by  Elsevier
ribe  of  Central  India,  the  Sahariya  tribe,  which  is
eported to  have  a very  high  incidence  and  preva-
ence of pulmonary  tuberculosis  [2,8—10]. This  can
e attributed  to  various  social  determinants  of  TB,
uch as  mal-nutrition,  overcrowding,  indoor  air  pol-
ution, young  age,  and  clinical  risk  factors,  like
iabetes  mellitus,  smoking,  alcohol  consumption,
mmunosuppressive  conditions,  and  socio-economic
s well  as  behavioral  factors,  all  play  an  impor-
ant role  [11].  Development  of  drug  resistance  in
. tuberculosis  isolates  may  worsen  the  TB  sce-
ario and  its  management.  Therefore,  this  study
imed  to  determine  the  situation  of  MDR-TB  in  the
ahariya  tribe  and  their  non-tribal  neighbors  n order
o develop  future  strategy  for  the  effective  control
f TB.
aterials and methods
tudy population and study design
 total  of  274  individuals,  185  from  the  Sahariya
ribe and  89  from  the  non-tribal  population,
ere screened  through  ﬁeld-based  investigations
rom the  Gwalior  and  Sheopur  districts  of  Madhya
radesh. The  participants  were  ﬁrst  screened  for
ymptoms.  Sputum  sampling  was  conducted  under
he supervision  of  a clinician.  The  individuals
ho had  a  conﬁrmed  diagnosis  of  TB,  based  on
iehl-Neelsen (ZN)  staining,  were  recruited  in
he study  after  obtaining  their  informed  consent.
he sampling  methods  and  protocols  employed
n the  study  were  approved  by  the  Institutional
thics Committee,  Jiwaji  University,  Gwalior.
he power  of  the  study  was  calculated  to  be
0—95%, using  a  power  and  sample  size  calculator
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www.stat.ubc.ca/∼rollin/stats/ssize/b2.html).
he calculated  sample  size  was  90  sputum  positive
amples for  both  the  Sahariya  tribe  and  non-tribes.
n Sahariya,  the  incidence  and  prevalence  of
B is  very  high,  hence,  we  collected  as  many
amples as  possible  to  deﬁne  the  etiology  of  drug
esistance  in  this  tribe.  The  non-tribe  samples
ere collected  as  controls.  All  the  patients,  either
ewly  diagnosed  or  previously  diagnosed,  were
nrolled  under  DOTS  (Directly  Observed  Treatment
hort Course)  chemotherapy  program  as  per  RNTCP
Revised  National  Tuberculosis  Control  Programme)
uidelines.
ample collection
he  sputum  samples  from  the  individuals  conﬁrmed
or TB  were  collected  in  sterile  sputum  vials  (Hi-
edia, Mumbai),  and  transported  to  the  laboratory,
here  they  were  processed  for  mycobacterial  cul-
ure using  modiﬁed  Petroff’s  method  and  incubated
n Lowenstein-Jensen  media  at  37 ◦C  for  approx-
mately 8  weeks  [12].  The  M.  tuberculosis  in  the
ulture  was  identiﬁed  by  biochemical  assays  [13].
rug susceptibility testing
he  drug  sensitivity  tests  for  the  ﬁrst  line  drugs
ere performed  using  the  standard  proportion
ethod [14].  The  ﬁrst  line  drugs,  viz.,  isoniazid,
ifampicin, ethambutol  and  streptomycin,  were
ncorporated  in  the  Lowenstein-Jensen  media  at  a
nal concentration  of  0.2  g/ml,  40  g/ml,  2  g/ml
nd 4  g/ml,  respectively,  and  then  incubated  at
7 ◦C.  A  two-third  loopful  of  M.  tuberculosis, rep-
esenting  an  approximately  4  mg  of  moist  weight
f bacterial  mass  was  scrapped,  and  transferred  to
 screw  cap  tube  containing  4—6  glass  beads  and
00 l of  distilled  water.  The  colonies  were  vor-
exed for  30  s  to  produce  a  uniform  suspension,
ollowed by  addition  of  sterile  distilled  water  and
hen left  for  approximately  15  min  to  permit  the
oarse  particles  to  settle  down.  The  opacity  of  the
uspension  was  matched  to  obtain  a  concentration
f 1  mg/ml  of  tubercle  bacilli  by  matching  it  with
 McFarland  standard.  From  this  standard  inocu-
um, 4  serial  dilutions  of  inoculum  at  concentrations
f 10−1,  10−2,  10−3 and  10−4, designated  as  S1,
2, S3  and  S4,  respectively,  were  made.  The  serial
ilutions  were  inoculated  in  the  drug-containing
nd drug-free  media  and  PNB  (Para  Nitro  Benzoic
cid) slope.  The  standard  laboratory  strain  H37Rv
as utilized  as  the  control.  The  growth  was  read
fter 28  and  42  days  and  recorded  as  3+  (conﬂu-
nt growth),  2+  (>100  colonies),  actual  number  of
olonies (1—100  colonies)  and  negative  (if  there
F
t
m
O291
as  no  growth).  The  highest  counts  obtained  on
rug-containing  and  drug-free  media  were  used  to
alculate the  proportion  of  resistant  bacilli.  Strains
ith 1%  bacilli  resistant  to  two  drugs,  namely,  iso-
iazid and  rifampicin,  were  graded  as  multidrug
esistant (MDR)  [14].
tatistical analysis
he  resistance  ratio  was  calculated  for  each
rug in  all  the  isolates  [14]. The  percentages
f monodrug  resistance,  multidrug  resistance  and
olydrug resistance  were  calculated  for  Sahariya
nd non-tribal  populations.  A  Chi-square  test  with
ate’s correction  was  applied  to  identify  any
ssociation between  the  drug-sensitive  isolates
o multidrug  resistance,  resistance  developed  to
ny drug,  overall  developed  drug  resistance  and
mokers/non-smokers  vs.  MDR-TB/non-MDR-TB  in
oth the  population  groups  using  Graph  Pad  Prism  6
oftware (www.graphpad.com). A  P-value  of  <0.05
as considered  statistically  signiﬁcant.
esults
he  mean  age  ±  standard  deviation  (SD)  between
ahariya (38.26  ±  13.67)  and  the  neighboring
on-tribal population  (39.74  ±  15.49)  was  non-
igniﬁcant  (P  =  0.4226).  No  statistically  signiﬁ-
ant difference  was  observed  in  age  between
ales (N  =  140,  39.2  ±  13.93)  and  females  (N  =  45,
5.3 ±  12.53)  of  Sahariya  tribe  (P  =  0.0961).  How-
ver, among  the  non-tribal  population,  the  age
as found  to  differ  signiﬁcantly  (P  = 0.0103)  among
ales (N  =  72,  41.7  ±  14.69)  and  females  (N  =  17,
1.1 ±  16.29).
A  comparison  between  MDR-TB  and  drug  sen-
itivity did  not  reveal  any  signiﬁcant  association
mong different  groups  of  Sahariya  and  the  non-
ribal population.  Further  comparison  between
esistance to  any  drug  and  drug  sensitivity  among
ifferent  groups  of  Sahariya  tribe  and  the  non-
ribal population  showed  signiﬁcant  difference
etween Sahariya  males  and  females  (P  = 0.0074,
R =  0.3368,  95%  CI  = 0.1579—0.7181)  (Table  1).
When the  overall  drug  resistance  was  compared
o the  sensitive  isolates  for  both  the  populations,
ahariya tribe  showed  a 1.95-fold  greater  risk  to
evelop  drug  resistance  than  their  non-tribal  neigh-
ors (P =  0.0315,  OR  =  1.959,  95%  CI  =  1.095—3.503).
urther stratiﬁcation  showed  signiﬁcant  associa-
ion of  developing  drug  sensitivity  among  Sahariya
ales compared  to  Sahariya  females  (P  =  0.0102,
R =  0.3879,  95%  CI  =  0.1951—0.7711).  However,
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Table  1  Chi-square  analysis  for  the  distribution  of  multidrug  resistant  isolates,  resistance  that  was  developed  to
any  drug  and  overall  drug  resistance  vs.  sensitive  isolates  in  the  Sahariya  tribe  and  the  non-tribal  population.
MDR-TB  vs.  sensitive  isolates
Groups  MDR-TB
N  =  27
(%)
Sensitive
N  =  187
(%)
ORa 95%  CIb P-value
Sahariya  tribe 21  (15) 118  (85) 2.047 0.7876—5.318 0.2011
Non-tribal  6  (8)  69  (92)
Sahariya  male  15  (13)  97  (87)  0.5412  0.1879—1.559  0.3950
Sahariya  female  6  (22)  21  (78)
Non-tribe  male  5  (8)  56  (92)  1.161  0.1247—10.80  0.6781
Non-tribe  female  1  (7)  13  (93)
Sahariya  male  15  (13)  97  (87)  1.732  0.5974—5.022  0.4399
Non-tribe  male  5  (8)  56  (92)
Sahariya  female  6  (22)  21  (78)  3.714  0.4003—34.46  0.4359
Non-tribe  female  1  (7)  13  (93)
Resistance  developed  to  any  drug  vs.  sensitive  isolates
Groups  Resistance  to
any  drug
N =  60
(%)
Sensitive
N  =  187
(%)
ORa 95%  CIb P-value
Sahariya  tribe  46  (28)  118  (72)  1.921  0.9850—3.748  0.0753
Non-tribal  14  (17)  69  (83)
Sahariya  male  28  (22)  97  (78)  0.3368  0.1579—0.7181  0.0074*
Sahariya  female  18  (46)  21  (54)
Non-tribe  male  11  (16)  56  (84)  0.8512  0.2073—3.495  0.8826
Non-tribe  female  3  (19)  13  (81)
Sahariya  male  28  (22)  97  (28)  1.470  0.6795—3.178  0.4273
Non-tribe  male  11  (16)  56  (84)
Sahariya  female  18  (46)  21  (54)  3.714  0.9116—15.13  0.1109
Non-tribe  female  3  (19)  13  (81)
Overall  drug  resistance  vs.  sensitive  isolates
Groups  Overall  drug
resistance
N  =  87
(%)
Sensitive
N  =  187
(%)
ORa 95%  CIb P-value
Sahariya  tribe  67  (36)  118  (64)  1.959  1.095—3.503  0.0315*
Non-tribal  20  (22)  69  (78)
Sahariya  male  43  (31)  97  (69)  0.3879  0.1951—0.7711  0.0102*
Sahariya  female  24  (53)  21  (47)
Non-tribe  male  16  (22)  56  (78)  0.9286  0.2657—3.245  0.8361
Non-tribe  female  4  (24)  13  (76)
Sahariya  male  43  (31)  97  (69)  1.552  0.8006—3.007  0.2523
Non-tribe  male  16  (22)  56  (78)
Sahariya  female  24  (53)  21  (47)  3.714  1.049—13.16  0.0691
Non-tribe  female  4  (24)  13  (76)
Bold values highlights the signiﬁcant differences.
* P < 0.05 is considered statistically signiﬁcant.
a OR, odds ratio.
b CI, conﬁdence interval.no  such  association  was  observed  in  either  the
non-tribal  population  (P  = 0.8361,  OR  = 0.9286,  95%
CI =  0.2657—3.245)  or  between  males  of  Sahariya
tribe and  non-tribes  (P  =  0.2523,  OR  =  1.552,  95%
C
b
C
wI  =  0.8006—3.007)  or  between  the  females  of
oth the  groups  (P  =  0.0691,  OR  = 3.714,  95%
I =  1.049—13.16)  (Table  1).  A  4.46-fold  risk
as observed  for  smokers  of  Sahariya  tribe
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Table  2  Chi-square  analysis  for  smokers  and  non-smokers  vs.  MDR  and  non  MDR-TB  in  the  Sahariya  tribe  and  the
non-tribal  population.
Groups  MDR-TB
N  =  27
(%)
Non-MDR  TB
N  =  247
(%)
ORa 95%  CIb P-value
Sahariya  tribe
Smokers  17  (18)  80  (82)
4.463 1.439—13.84 0.0109*Non-Smokers  4  (5)  84  (95)
Non-tribe
Smokers  1  (9) 10  (91)
1.460 0.1543—13.81 0.7563Non-Smokers  5  (6) 73  (94)
Bold values highlights the signiﬁcant differences.
* P < 0.05 is considered statistically signiﬁcant.
a OR, odds ratio.
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o  develop  MDR-TB  (P  =  0.0109,  OR  =  4.463,  95%
I = 1.439—13.84),  whereas,  no  signiﬁcant  asso-
iation could  be  observed  for  the  non-tribes
P = 0.7563,  OR  =  1.460,  95%  CI  =  0.1543—13.81)
Table  2).
The possibility  of  developing  multidrug  resis-
ance in  a  particular  age  group  among  the  Sahariya
ribe and  non-tribal  population  was  also  analyzed
hich did  not  reveal  any  signiﬁcant  association
Table  3).
When drug  resistance  to  any  one  of  the  four
rugs used  in  chemotherapy  and  multidrug  resis-
ance  were  compared  among  new  smear  positive
NSP) cases  of  Sahariya  and  the  non-tribal  patients,
he number  of  individuals  developing  drug  resis-
ance to  isoniazid  alone  or  in  combination  with
ifampicin were  observed  to  be  higher  in  Sahariya
INH =  14%,  INH  + RIF  = 11%)  than  in  the  non-tribal
opulation (INH  =  7%,  INH  + RIF  = 7%).  The  resistance
eveloped to  isoniazid  alone  in  retreated  and  treat-
ent after  default  (TAD)  or  defaulter  patients,
evealed a  high  percentage  of  isoniazid  resistance
n retreated  and  TAD  patients  of  Sahariya  (16%  and
1%, respectively),  but,  in  non-tribal  population  the
nly isoniazid  alone  resistance  was  found  negligi-
le, when  compared  (Table  4).
Fewer numbers  of  isolates,  who  developed  resis-
ance  in  different  combinations  of  isoniazid  in
elapse and  TAD  cases,  were  observed  in  both  the
opulation  groups.  In  Sahariya  tribe,  the  maxi-
um number  of  MDR-TB  cases  (N  =  16,  11%)  was
bserved among  new  smear  positive  cases,  which
howed  primary  drug  resistance.  The  number  of
ases among  retreated  and  defaulter  (TAD)  cate-
ories  were  very  few.  However,  a  high  percentage
f individuals  (cases)  developing  primary  resistance
as observed  among  patients  of  both,  the  Sahariya
ribe and  the  non-tribal  populations.  However,  the
r
s
w
tumber  of  MDR-TB  for  retreated  and  treatment
fter default  cases  in  the  non-tribal  population
as very  few  (N  =  5,  7%).  The  resistance  to  isoni-
zid was  more  commonly  observed,  followed  by
ifampicin,  ethambutol  and  streptomycin.  In  the
ahariya tribe,  resistance  to  isoniazid  (H)  and  isoni-
zid plus  rifampicin  (HR)  constituted  14%  and  11%,
espectively,  whereas,  for  the  non-tribal  popula-
ion, it  was  only  7%  in  both  cases  (Table  4).
iscussion
ndia  has  the  highest  MDR-TB  burden  with  99,000
stimated  incident  TB  cases.  This  indicates  that
he prevalence  of  MDR-TB  is  slowly  growing  up  in
he country  [15].  This  is  the  ﬁrst  study  to  reveal
he MDR-TB  situation  in  a Central  Indian  tribe,
ahariya and  their  non-tribal  neighbors.  The  preva-
ence of TB  is  already  reported  to  be  very  high
1518/100,000 people)  in  Sahariya  [2]. The  crude
revalence  of  TB  is also  observed  to  be  high  in
he tribes  (29.9%)  as  compared  to  the  non-tribal
opulation (21.4%)  [8]. The  present  study  indi-
ates a  increased  rate  of  MDR-TB  in  the  Sahariya
ribe than  in  the  neighboring  non-tribal  popula-
ion, although  statistically  no  signiﬁcant  association
ould be  observed.
A comparison  between  resistance  to  any  drug  and
ensitive  isolates  revealed  that  Sahariya  males  are
ess prone  to  any  drug  resistance  (or  more  sensi-
ive to  any  drug)  than  females.  The  Sahariya  tribe
ad a  1.9-fold  higher  risk  of developing  overall  drug
esistance  than  non-tribes.  Further,  gender  based
tratiﬁcation  also  showed  that  Sahariya  females
ere at  a  higher  risk  of  overall  drug  resistance
han males  (or  vice-a-versa,  i.e.,  overall,  males  are
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Table  3  Age  group  vs.  pattern  of  multidrug  resistance  among  Sahariya  tribe  and  their  non-tribal  neighbors.
Characteristics  Sahariya  tribe  Non-tribe  ORa 95%  CIb P-value
Age  (years)
15—24  6  1  2.000  0.1913—20.91  0.9532
25—34  7  1  2.500  0.2429—25.73  0.7782
35—44  3  1  0.8333  0.07041—9.864  0.6123
45—54  4  1  1.176  0.1059—13.07  0.6431
55—64 0  2  0.04186  0.001702—1.030  0.0621
>64  1  0  0.9512 0.03436—26.33  0.4959
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na OR, odds ratio.
b CI, conﬁdence interval.
less  prone  to  drug  resistance/or  more  sensitive  to
drugs).
A high  percentage  of  women  developing  drug
resistance among  new  smear  positive  cases  was
observed  for  Sahariya  tribe.  Females  were  also
found  to  have  a  high  percentage  of  MDR-TB,  resis-
tance  developed  to  any  drug  and  overall  drug
resistance when  compared  in  both  the  population
groups. Similar  studies  from  Georgia  also  revealed
that females  were  at  1.36  [16]  to  1.6  [17]  fold
higher risk  of  developing  MDR-TB.  On  the  contrary,
Faustini  et  al.  reported  tuberculosis  and  MDR-TB  to
be more  common  among  men  [18]. In  Central  Nepal
also, males  were  observed  to  have  more  MDR-TB
(65.5%) more  than  females  (34.5%)  [19].  However,  it
is suggested  that  in  males,  the  association  between
previous  treatment  and  MDR-TB  may  be  modiﬁed
[17].  The  reason  for  the  association  of  female  gen-
der with  MDR-TB  remain,  unclear.  A  likely  possibility
is that  women  exert  an  important  inﬂuence  on
health habits  in  the  family  because  of  their  social
role as  nurturer  and  care  takers  of  the  young,  old
and sick  members  of  the  family.  Attending  men  and
others with  MDR-TB,  carrying  the  social  stigma  of
not leaving  the  home,  poor  health  care  facilities  in
the rural  areas  and  low  ventilated  houses  increase
the risk  of  transmission  of  drug  resistant  bacteria
in them.  A  4.4-fold  increase  in  risk  was  observed  in
smokers  and  tobacco  chewers  of  Sahariya  tribe  to
develop  MDR-TB.  However,  no  signiﬁcant  associa-
tion  of  smoking  was  observed  among  the  non-tribal
patients. This  observation  is in  accordance  with  an
earlier report  that  smoking  and  alcohol  consump-
tion increases  the  risk  of  TB  in  Sahariya  tribe  [20].
Smoking and  alcohol  abuse  at  working  places  and
more signiﬁcantly,  at  an  early  age,  are  also  predis-
posing  factors  for  high  prevalence  of  TB  in  Sahariya
men  [8,20,21].
Further,  the  prevalence  of  TB  (0.382)  was
reported higher  in  Sahariya  males  (20—40  years)
than in  Sahariya  females  (0.142)  [21]  as  well  as
in non-tribal  males  [8]. One  of  the  most  likely
reasons for  the  increased  incidence  of  TB  and
t
B
d
wDR-TB  in  males  of  Sahariya  could  be  because
hey start  smoking  at a  very  early  age  as  com-
ared to  non-tribes.  While,  working  as  laborers  they
hare the  same  environment  and  smoking  sticks
ith infected  individuals.  The  high  rate  of  MDR-
B in  this  community  may  also  be  due  to  several
easons, such  as  their  remote  habitation,  often  dif-
cult to  reach  to  a  health  care  facility,  or  poor
r total  absence  of  required  health  care  facili-
ies, lack  of  clarity  of  medical  instructions,  poor
ife style,  malnutrition,  drug  mal-absorption,  non-
dherence  to  recommended  treatment  regimen  or
he treatments,  followed  by  interference  of  private
ractitioners  in  the  rural  areas  who  usually  do  not
ollow the  standard  regimen  of  DOTS  or  the  duration
f chemotherapy  as  per  the  RNTCP  criteria  [22,23].
hus, all  or  most  of  the  above  factors,  including
heir social  behavior,  when  compared  with  their
on-tribal  neighbors,  could  be  signiﬁcantly  con-
ributing  to  such  a high  rate  of  MDR-TB  in  Sahariya.
An earlier  study  on  Sahariya  has  reported  sta-
istically signiﬁcant  increase  in  the  prevalence  of
B with  age  and  in  males  (P  <  0.001)  [2]. It  was
lso suggested  that  presumptive  MDR-TB  patients
elow  26  years  of  age  have  a  2.9-fold  higher  risk
f developing  MDR-TB  than  TB  patients  in  the  age
roup more  than  26  years  old  [24]. However,  the
resent  study  did  not  ﬁnd  any  signiﬁcant  association
etween Sahariya  tribe  and  the  non-tribal  popula-
ion when  stratiﬁed  on  the  basis  of  age  groups.
In Sahariya  tribe,  the  East  African  Indian
EAI3 IND/ST11)  strain  is  found  more  prevalent  (MS
ommunicated),  which  has  been  described  as  an
ncient strain  [25]. The  EAI3  IND  is  less  prevalent
n North  India  (32%)  but,  is  more  (52%)  prevalent
n Central  India  and  is  signiﬁcantly  high  in  South
ndia  (80%)  [26—29]. In  non-tribes,  however  the
AS1 Delhi  is the  predominant  strain  (MS  commu-
icated). Earlier  studies  also  reported  this  strain
o be  most  common  in  Northern  India  [28—31].  The
eijing  strain  was  observed  strongly  associated  with
rug resistance  [32,33]. However,  in  our  study;  it
as completely  absent  in  the  Sahariya  population;
Drug  resistance  in  Sahariya  tribe  
Ta
bl
e  
4  
Pr
ev
al
en
ce
 
of
 
dr
ug
 
re
si
st
an
ce
 
am
on
g 
M
. 
tb
 
is
ol
at
es
 
fr
om
 
pr
ev
io
us
ly
 
tr
ea
te
d 
ca
se
s 
ac
co
rd
in
g 
to
 
th
e 
dr
ug
 
an
d 
th
e 
ty
pe
 
of
 
ca
se
 
fr
om
 
th
e 
Sa
ha
ri
ya
 
tr
ib
al
 
an
d
no
n-
tr
ib
al
 
po
pu
la
ti
on
.
D
ru
g 
re
si
st
an
ce
 
Sa
ha
ri
ya
 
tr
ib
e
(N
 
=  
18
5)
N
 
(%
)
N
on
-t
ri
ba
l
(N
 
=  
89
)
N
 
(%
)
N
SP
(N
 
=  
14
0)
Re
tr
ea
te
d
(N
 
=  
18
)
TA
D
(N
 
=  
27
)
To
ta
l
(N
 
=  
18
5)
N
SP
(N
 
=  
72
)
Re
tr
ea
te
d
(N
 
=  
7)
TA
D
(N
 
=  
10
)
To
ta
l
(N
 
=  
89
)
Re
si
st
an
ce
 
to
 
an
y  
dr
ug
31
 
(2
2)
4  
(2
2)
5  
(1
9)
40
 
(2
2)
10
 
(1
4)
1  
(1
4)
1  
(1
0)
12
 
(1
3)
M
D
R  
Is
ol
at
es
 
16
 
(1
1)
 
2 
(1
1)
 
3 
(1
1)
 
21
 
(1
1)
 
5 
(7
) 
1 
(1
4)
 
0 
6 
(7
)
Re
si
st
an
ce
 
to
 
on
ly
 
on
e  
dr
ug
R  
6  
(4
)
0  
2  
(7
)
8  
(4
)
2  
(3
)
1  
(1
4)
0  
3  
(3
)
H
 
20
 
(1
4)
 
3 
(1
6)
 
3 
(1
1)
 
26
 
(1
4)
 
5 
(7
) 
0 
0 
5 
(6
)
Re
si
st
an
ce
 
in
 
di
ff
er
en
t  
co
m
bi
na
ti
on
s  
of
 
dr
ug
s
H
 
+  
R
16
 
(1
1)
2  
(1
1)
3  
(1
1)
21
 
(1
1)
5  
(7
)
1  
(1
4)
0  
6  
(7
)
H
 
+ 
S 
2 
(1
) 
1 
(6
) 
0 
3 
(1
) 
1 
(1
) 
1 
(1
4)
 
1 
(1
0)
 
3 
(3
)
H
 
+  
E
2  
(1
)
0  
0  
2 
(1
)
1  
(1
)
0  
0  
1  
(1
)
H
 
+  
R  
+  
S
0 
1  
(6
)
0  
1  
(0
.5
)
0  
0  
0  
0
H
 
+ 
R 
+ 
E 
0 
0 
0 
0 
0 
0 
0 
0
H
 
+  
R  
+  
S  
+  
E
0 
0  
0  
0  
0  
0  
0  
0
Se
ns
it
iv
e  
87
 
(6
2)
 
12
 
(6
7)
 
19
 
(7
0)
 
11
8 
(6
4)
 
56
 
(7
8)
 
4 
(5
7)
 
9 
(9
0)
 
69
 
(7
8)
Ab
br
ev
ia
ti
on
s:
 
E,
 
et
ha
m
bu
to
l;
 
H
, 
is
on
ia
zi
d;
 
R,
 
ri
fa
m
pi
ci
n;
 
S,
 
st
re
pt
om
yc
in
.
w
j
E
d
t
i
p
c
2
u
w
ﬁ
s
w
o
6
b
m
d
T
a
t
c
T
s
o
B
M
p
b
g
r
N
s
i
3
2
f
i
M
A
f
p
1
l
p
[
a
u
w
t
f
n
p295
hereas,  in  non-tribes,  only  1  Beijing  and  2  Bei-
ing like  strains  were  observed.  This  indicates  that
AI3 IND  and  CAS1  Delhi  strains  may  be  developing
rug resistance  more  slowly  and  may  pose  a  major
hreat  to  Sahariya  in  future.
In Sahariya,  11%  of  MDR-TB  cases  were  observed
n the  NSP,  retreated  and  TAD  categories  of
atients. The  percentage  of  drug  resistance  in  NSP
ases was  higher  than  the  national  average,  i.e.,
.1% of  MDR-TB  cases  [34].  In  the  non-tribal  pop-
lation,  7%  of  MDR-TB  cases  were  found  in  NSP,
hereas, 14%  were  retreated  and  TAD  cases.  Our
nding  on  a high  rate  of MDR-TB  cases  for  new
mear positive  cases  in  Sahariya  corresponds  well
ith a  study  from  Kashmir,  where  primary  and  sec-
ndary drug  resistance  was  observed  at  36.5%  and
3.4%, respectively  [35]. The  rates  of  MDR-TB  have
een reported  to  range  from  4%  (Dashoguz,  Turk-
enistan)  to  22.7%  (Samara,  Russia),  with  primary
rug resistance  [36,37]  and  from  18%  (in  Dashoguz,
urkmenistan)  to  54—60%  (in  Republic  of  Lithuania
nd Arkhangelsk,  Russia)  for  acquired  drug  resis-
ance [36,38,39]. An  increase  in  multidrug  resistant
ases has  also  been  reported  from  Estonia  (12.2%),
omsk,  the  Russian  Federation  (13.7%)  and  Kazakh-
tan (14.2%)  [40]. In  contrast,  in  a  recent  study
n Sahariya  in  the  Gwalior  and  Shivpuri  districts,
hat and  colleagues  observed  3% of NSP  cases  with
DR-TB  and  12—17%  in  retreated  cases  [41].  The
revalence  of  multidrug  resistant  TB  infection  has
een observed  to  vary  widely  across  different  geo-
raphical  locations  with  a  high  rate  of  infection
eported from  Nepal  (48%),  Gujarat,  India  (34%),
ew York,  USA  (30%)  and  South  Korea  (15%)  [42].  A
tudy from  Northern  India  revealed  continuous  and
ncreasing  trend  of  MDR-TB  infection,  i.e.,  36.4%,
6.7%, 39.1%  and  40.8%  in  the  years  2007,  2008,
009 and  2010,  respectively  [43]. In  another  study
rom Northern  India,  on  the  prevalence  of  MDR-TB
nfection, out  of  196  cases,  40  patients  (20.4%)  had
DR-TB [44]. Recently,  Yimer  and  colleagues  from
mara region  of  Ethiopia,  reported  a 16.9%  overall
requency  of  resistance  to  any  drug,  while  the  pro-
ortion of  monodrug,  polydrug  and  MDR-TB  were
2.6%, 3.9%  and  0.9%,  respectively  [45].
TB has  remained  a  major  public  health  prob-
em in  Sahariya  tribe  since  the  time  of  ﬁrst  report
ublished  in  1996  on  TB  prevalence  in  this  tribe
46]. The  living  conditions  of  Sahariya  tribe  are
dverse.  They  live  in  forests,  remote  areas  and
nder  improper  sanitary  and  unhygienic  conditions,
ith lack  of  safe  drinking  water  and  more  impor-
antly, at  a long  distance  from  necessary  health  care
acilities. Forced  migration  in  search  of  work  and
on-compliance  of  patients  to  the  chemotherapy
rovided under  RNTCP  programe  could  be  the  other
ﬁ
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strong  reasons  for  the  increased  rate  of  MDR-TB  in
them. The  present  study  can  be  used  as  baseline
data for  MDR-TB  among  Sahariya  tribe  and  the  non-
tribal population  and  focuses  the  need  of active
interference to  control  the  transmission  of  MDR-TB
cases,  especially  in  rural  and  remote  areas.
Our study  has  certain  limitations  too.  It  is  a  ﬁeld-
based  investigation;  the  tribal  people  sometimes  do
not reveal  the  exact  history  of  the  disease  or  if  they
had taken  DOTS  earlier  or  not.  In  addition,  they
often follow  treatment  procedures  from  private
practitioners who  do  not  adhere  to  the  standard
treatment regimen  of  DOTS.  Another  limitation  is
that the  HIV  status  was  not  examined  in  the  study
population.
Conclusion
In conclusion,  the  present  investigation  indicated
that drug-resistant  tuberculosis  is  emerging  as  a
serious public  health  concern  in  the  Sahariya  tribe.
An adequate  monitoring  of  the  treatment  regimens
for MDR-TB  in  the  tuberculosis  control  program
is needed  among  tribal  communities,  such  as
Sahariya,  particularly  in  new  smear  positive  cases
(before  it  aggravates  further).  The  present  observa-
tions  may  be  considered  as  alarm  for  a  more  serious
condition  that  may  occur  in  future.  An  urgent  and
effective  strategy  needs  to  be  designed  for  the
prevention of  MDR-TB,  which  is  essential  to  check
the increasing  trend  of  TB  incidence/prevalence
in  this  tribal  population.  Further,  research  is  also
required  to  determine  the  transmission  dynamics
of drug-resistant  strains  in  this  tribe  compared  to
its non-tribal  neighbors.
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